Abstract
Background
Although postoperative radiotherapy (RT) after breast-conserving surgery (BCS) halves the 10-year recurrence rate in breast cancer patients through all age groups, the question of whether RT may be omitted and replaced by endocrine therapy for women aged 70 years and older with low-risk factors has recently become an issue of debate.
Methods
Survey of the relevant recent literature (Medline) and international guidelines.
Results
Three randomized studies investigating the effect of RT in older women revealed significantly increased local recurrence rates when RT was omitted, and a negative impact on disease-free survival was observed in two of these trials. Despite these findings, in one of the studies omission of RT in women over 70 is recommended, leading to a respective amendment in the guidelines of the American National Comprehensive Cancer Network. Several large retrospective cohort studies analyzing the outcome of patients over 65 years with and without RT have since been published and showed a significantly improved local control in all subgroups of advanced age and stage, which predominantly translated into improved disease-free and overall survival.
Conclusion
No subgroup of elderly patients has yet been identified that did not profit from RT in terms of local control. Therefore, chronological age alone is not an appropriate criterion for deciding against or in favor of adjuvant RT. The DEGRO breast cancer expert panel explicitly discourages determination of a certain age for the omission of postoperative RT in healthy elderly women with low-risk breast cancer. For frail elderly women, treatment decisions should be individually decided on the basis of standardized geriatric assessment.
Zusammenfassung
Hintergrund
Nach brusterhaltender Operation wird die 10-Jahres-Rezidivrate bei Brustkrebspatientinnen sämtlicher Altersgruppen durch eine postoperative Radiotherapie (RT) halbiert. Dennoch ist neuerdings eine Kontroverse darüber entbrannt, ob bei Frauen über 70 Jahre mit niedrigem Risikoprofil auf die RT verzichtet und stattdessen eine endokrine Therapie erfolgen solle.
Methoden
Literaturrecherche der kürzlich zu diesem Thema publizierten Studien (Medline) und internationaler Leitlinien.
Resultate
In drei randomisierten Studien wurde die Effektivität der RT bei älteren Frauen untersucht und zeigte eine signifikant höhere Lokalrezidivrate bei Nichtbestrahlten sowie in zwei dieser Studien einen negativen Einfluss auf das krankheitsfreie Überleben. Dennoch wurde in einer Publikation der Verzicht auf eine RT bei >70-Jährigen empfohlen, was als Ergänzung in die aktuellen amerikanischen National-Comprehensive-Cancer-Network-Leitline übernommen wurde. Seitdem wurde in mehreren umfangreichen Kohortenstudien der Verlauf von Patientinnen >65 Jahre mit und ohne RT ausgewertet, wobei sich in sämtlichen Alterssubgruppen und Tumorstadien der >65-Jährigen eine signifikant verbesserte lokale Tumorkontrolle nach RT zeigte, die überwiegend auch zu einem verlängerten rezidivfreien und Gesamtüberleben führte.
Schussfolgerung
Bislang wurde keine Subgruppe älterer Patientinnen identifiziert, die nicht durch Senkung der Lokalrezidivrate von einer RT profitierten. Die DEGRO-Expertengruppe Mammakarzinom sieht deshalb das kalendarische Alter allein nicht als hinreichendes Entscheidungskriterium gegen eine RT, diese sollte deshalb älteren Patientinnen in gutem Allgemeinzustand nicht vorenthalten werden. Bei gebrechlichen Älteren ist eine individuelle Entscheidung anhand eines standardisierten geriatrischen Assessments zu treffen.
References
AGO (2012) Diagnostik und Therapie primärer und metastasierter Mammakarzinome – Adjuvante Strahlentherapie. http://www.ago-online.de
Albert JM, Liu DD, Shen Y et al (2012) Nomogram to predict the benefit of, radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 30:2837–2843
Balducci L (2003) Geriatric oncology. Crit Rev Oncol Hematol 46:211–220
Biganzoli L, Wildiers H, Oakman C et al (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160
Bouchardy C, Rapiti E, Fioretta G (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580–3587
Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 378:1707–1716
Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322
Deutsch M (2002) Radiotherapy after lumpectomy for breast cancer in very old women. Am J Clin Oncol 25:48–49
Extermann M, Aapro M, Bernabei R et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–252
Fyles AW, McCready DR, Manchul LA et al (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963–970
Giordano SH (2012) Radiotherapy in older women with low-risk breast cancer: why did practice not change? J Clin Oncol 30(14):1577–1578
Giordano FA, Wenz F (2012) Nachteile für ältere Patientinnen mit Mammakarzinom durch Untertherapie. Strahlenther Onkol 188:527–528
Greenup RA, Camp MS, Taghian AG et al (2012) Comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol (Epub ahead of print)
Hancke K, Denkinger MD, König J et al (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21:748–753
Hughes KS, Schnaper LA, Berry D et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. N Engl J Med 351:971–977
Hughes KS, Schnaper LA, Cirrincione C et al (2010) Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol 28:69 s (suppl 15, abstr 507)
Jahrbuch Statistisches Bundesamt für die Bundesrepublik Deutschland 2008: http://www.destatis.de
Jenkins PL, May VE, Hughes LE (1991) Psychological morbidity associated with local recur-rence of breast cancer. Int J Psychiatry Med 21:149–155
Klusmann V, Evers A, Schwarzer R et al (2010) Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. J Gerontol A Biol Sci Med Sci 65(6):680–688
Leitlinienprogramm Onkologie DKG, Deutsche Krebshilfe, AWMF (2012) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. http://www.senologie.org/fileadmin/downloads/S3-Brustkrebs-v2012-OL-Langversion.pdf
Muss HB, Tu D, Ingle JN (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26(12):1956–1964
National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555
Pötter R, Gnant M, Kwasny W (2007) Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68(2):334–340
Robert Koch Institut (2012) Krebs in Deutschland 2007–2008. Häufigkeiten und Trends, 8. überarbeitete Aufl. In: Robert-Koch-Institut, die Gesellschaft für epidemiologische Krebsregister in Deutschland e.V. (Hrsg) Robert Koch Institut, Berlin
Sautter-Bihl ML, Sedlmayer F, Budach W et al (2010) Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer: beware of one-stop shops? Strahlenther Onkol 86(12):651–657
Sautter-Bihl ML, Souchon R, Gerber B (2011) Adjuvant therapy for women over age 65 with breast cancer. Dtsch Ärztebl. Int 108 (21):365–371
Smith BD, Jiang J, McLaughlin SS et al (2011) Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 29(35):4647–4653
Soulos PR, Yu JB, Roberts KB et al (2012) Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J Clin Oncol 30(14)1601–1607
START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG et al (2008).The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9:331–341
START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG et al (2008).The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107
Truong PT, Bernstein V, Lesperance M et al (2006) Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg 191:749–755
Vitetta L, Anton B (2007) Lifestyle and nutrition, caloric restriction, mitochondrial health and hormones: scientific interventions for anti-aging. Clin Interv Aging 2(4):537–543
Wazer DE (2012) Measuring the value of radiotherapy in older women with breast cancer. J Clin Oncol 30(23):2809–2811
WhelanTJ, Pignol JP, Levine MN (2010) Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520
Williams LJ, Kunkler IH, King CC (2011) A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial. Health Technol Assess. (12):i-xi, 1–57
Winzer KJ, Gruber C, Badakhshi H (2012)Compliance of patients concerning recommended radiotherapy in breast cancer: Association with recurrence, age, and hormonal therapy. Strahlenther Onkol 188(9):788–794
Wong J, D’Alimonte L, Angus J et al (2012) Development of patients’ decision aid for older women with stage I breast cancer considering radiotherapy after lumpectomy. Int J Radiat Oncol Biol Phys 84(1):30–38
Yood Y MU, Owusu C, Buist DS et al (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206:66–75
Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol.3:431–436
Conflict of interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sautter-Bihl, M., Sedlmayer, F., Budach, W. et al. When are breast cancer patients old enough for the quitclaim of local control?. Strahlenther Onkol 188, 1069–1073 (2012). https://doi.org/10.1007/s00066-012-0253-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-012-0253-6
Keywords
- Breast cancer
- Life expectancy
- Older patients
- European Society of Breast Cancer Specialists guidelines
- Radiotherapy